Z P ] } v o } v } Z ' o } o ] } v o v } v u v ] ~ µ } · (xurshdq 'hphqwld 0rqlwru 3ulrulw\ duhdv...

$: Z P ] } v o } v } Z ' o } o ] } v o v } v u v ] ~ µ } · (xurshdq 'hphqwld 0rqlwru 3ulrulw\ duhdv $ydlodelolw\ ri fduh vhuylfhv $iirugdelolw\ ri fduh vhuylfhv ilqdqflqj 7uhdwphqw$
Regional response to the Global action plan on dementia (Europe)

ADI Conference, Chicago – 27 July 2018

Jean Georges, Executive Director

@JeanGeorgesAE

2

Alzheimer Europe

40 associations in 35 countries

European Dementia Monitor - Concept• Benchmarking of national dementia policies (comparison and

ranking)

• Possibility to repeat and show changes in rankings

• Lobbying tool for AE to present comparative data to European Parliament, European Commission and WHO/Europe (inequalities in access to care and treatment)

• Lobbying tool for national Alzheimer associations (compare national situation to other countries)

3

European Dementia Monitor - Priority areas

• Availability of care services

• Affordability of care services (financing)

• Treatment-reimbursement of AD medicines

• Access to clinical trials

• Involvement of country in EU dementia research

• Recognition of dementia as a priority

• Dementia friendly Communities/Inclusiveness

• Recognition of legal rights

• Recognition of human rights

• Employment carer/employment support

4

5

Recognition of dementia as a priority• Is dementia recognised as a research priority?

• Is a national strategy in place or in development?

• Does the strategy have specific allocated funding?

• Is there a Government appointed person in charge of the coordination of dementia policies?

• Does the national Alzheimer’s association receive funding from Government for its core activities or central office?

• Does the national Alzheimer’s association receive funding from government programmes for projects or specific services?

6

7

Clinical Trials• Phase III

• Available in at least two European countries

• 9 clinical trials investigating different compounds (Aducanumab, Bexipiprazole, CAD106, Crenezumab, Idalopirdine, JNJ-54861911, LY3314814, RVT-101 and Varubecestat)

8

9

Dementia friendliness• Working group of people with dementia

• Dementia friends programme

• Dementia-friendly communities

– Developed concept

– In development

10

11

Overall ranking• Each section contributes 10% to the overall score

12

13

Concluding remarks• Growing recognition of dementia as a European priority

– Need for increased funding and improved coordination at European and global level

– Need for benchmarking and comparison tools such as WHO Global Dementia Observatory

• Inequalities across European countries

– Need for dementia strategies and increased dementia awareness in all European countries

14

Z P ] } v o } v } Z ' o } o ] } v o v } v u v ] ~ µ } · (xurshdq 'hphqwld 0rqlwru 3ulrulw\ duhdv...

Documents

Transcript of Z P ] } v o } v } Z ' o } o ] } v o v } v u v ] ~ µ } · (xurshdq 'hphqwld 0rqlwru 3ulrulw\ duhdv...